Related to Positive Results Reported for Biogen Idec’s Oral MS Drug in First Phase III Study

• Phase III Trial Demonstrates Benefits of Teva’s Laquinimod in MS Patients
  
• Biogen Idec’s Fampyra for MS Fails to Win CHMP Support in Europe
  
• Protagen to Help Biogen Idec Find Biomarkers for Multiple Sclerosis Therapy
  
• Australia Approves Biogen Idec’s Fampyra for Improving Walking Ability in Multiple Sclerosis
  
• EU Approves Biogen Idec’s Avonex Intramuscular Autoinjector Product for MS
  
• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• EC Conditionally Approves Biogen Idec’s Multiple Sclerosis Drug Fampyra
  
• Sanofi and Genzyme Report Positive New Data from Phase III Multiple Sclerosis Study
  
• Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug
  
• Genzyme’s mAb for Multiple Sclerosis Succeeds in Second Phase III Trial
  
• Genzyme Reports Data from Late-Stage MS Study
  
• FDA Approves Tysabri Label Change and Test for JC Virus Infection in MS Patients
  
• Biogen Idec Takes Option to MAKScientific MS Program
  
• Genzyme’s MS Therapy Teriflunomide Shows Positive Initial Results in Third Phase III Trial
  
• Regulus, Biogen Idec Partner on MS Biomarkers
  
• $3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan
  
• Biogen Idec Prepares to Launch 4th MS Drug
  
• Promising Results for MS Drug in Two Phase III Trials
  
• Biogen Idec's Multiple Sclerosis Drug Meets All Endpoints in First Phase III Trial
  
• Biogen Idec Reports Positive Data from Second Phase III Trial with Multiple Sclerosis Drug